The global NGS reference materials market was valued at USD 293.4 million in 2025. The market is estimated at USD 327.3 million in 2026 and is projected to reach USD 904.1 million by 2036, at a CAGR of 10.7% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering clinical sequencing growth, validation needs, reference material technologies, standards consortia, regulation, pricing, the competitive landscape, and future growth opportunities.
The market, also described as the NGS controls and reference standards market, includes well-characterized biological and synthetic materials of known composition that laboratories and assay makers use to build, validate, verify, and monitor next-generation sequencing tests. Cell line-derived materials in genomic DNA and FFPE formats, synthetic and engineered constructs such as plasmids, oligonucleotides, and in vitro transcribed RNA, contrived materials formulated in plasma, blood, or saliva, whole-genome and certified materials from metrology institutes, microbial and metagenomic standards are in scope, in research-use-only and IVD-labeled grades. Sequencing instruments and reagents, library preparation and extraction kits, PCR-only controls, proficiency testing services, and stand-alone software are excluded.
Sequencing capacity keeps rising, which widens the base of assays that need validation: Illumina, Inc. reported second-quarter 2026 sequencing consumables revenue of USD 775 million, up 5%, and instrument revenue of USD 125 million, up 31%. Clinical oncology testing is also growing, as Tempus AI, Inc. reported that its oncology testing volume grew 31% in the same quarter, when it also ran 9,000 residual disease tests. Standardization is also moving ahead, as NIST, through its Genome in a Bottle Consortium, supplies certified genome materials RM 8391, RM 8392, and RM 8393 together with benchmark variant call sets.
Some large academic centers and reference laboratories rely on residual patient samples instead of commercial materials, as these specimens are commutable by nature and cost little, although they are scarce, variable, and cannot be reordered. Smaller laboratories under reimbursement pressure may cut quality control frequency, run fewer replicates, or buy narrower materials. Commutability is a major technical challenge, since engineered materials can differ from clinical samples in fragmentation, chemical modification, background complexity, and matrix, with FFPE tissue and cell-free DNA the hardest to mimic. Characterizing every variant in a multiplex material needs orthogonal methods and replicate testing, and expectations still vary between accreditation bodies and jurisdictions.
IVD-labeled and regulated-grade standards are a major opportunity; in June 2025, Revvity, Inc. launched its first IVD-labeled Mimix standards, including OncoSpan FFPE, OncoSpan gDNA, and Myeloid Cancer Panel gDNA products developed under design controls to meet FDA requirements. Under the EU In Vitro Diagnostic Regulation, makers of Class C self-declared devices were required to have a written notified body agreement in place by September 26, 2026 to continue selling legacy devices through 2028, which raises demand for documented, traceable materials. Further openings lie in RNA, fusion, and complex biomarker standards, standards that support cell and gene therapy characterization, and microbial and metagenomic controls for public health laboratories. Key trends include consortium-developed consensus materials, a shift toward multiplex and panel-matched products, and the bundling of materials with benchmark data and analytical support.
By product type, the NGS reference materials market is segmented into cell line-derived, synthetic & engineered, contrived in matrix, whole-genome & certified, and microbial & metagenomic reference materials. Cell line-derived materials are expected to hold the largest share in 2026, as cell lines keep the genomic complexity of real samples so assays are tested against a realistic background, they come in genomic DNA and FFPE formats that match what clinical laboratories process, and they are long established in oncology validation, as seen in Revvity's OncoSpan and Myeloid Cancer Panel standards. Contrived materials in matrix are expected to grow at the highest CAGR, driven by liquid biopsy and residual disease testing that needs plasma-formulated materials at low, precise allele frequencies, and by growing awareness that conventional genomic DNA standards do not reflect how cell-free DNA assays perform. Synthetic and engineered materials, such as plasmid, oligonucleotide, and in vitro transcribed RNA constructs, complement cell line products.
By type, the NGS reference materials market is segmented into multiplex and single-variant reference materials. Multiplex materials are expected to account for the largest share in 2026 and to grow at the highest CAGR during the forecast period. Modern clinical panels report many genes and several variant classes, so validating them with single-variant controls would take an impractical number of samples, whereas one multiplex material can challenge many variants at once, and newer products pair DNA with RNA so that fusions are covered as well. Single-variant materials remain useful for tracking specific actionable variants and for companion diagnostic work.
By application, the NGS reference materials market is segmented into oncology, liquid biopsy & molecular residual disease, inherited & rare disease, reproductive health, infectious disease & microbiology, and other applications. Oncology is expected to account for the largest share in 2026, given the high volume of comprehensive genomic profiling, the wide range of variant classes oncology panels must cover, the clinical risk of missing an actionable variant, and the maturity of multiplex oncology materials, including consensus standards from the MDIC Somatic Reference Samples Initiative. Liquid biopsy & molecular residual disease is expected to grow at the highest CAGR, supported by fast uptake of circulating tumor DNA testing and residual disease monitoring and by the demanding specifications these assays place on reference materials. The other applications category spans pharmacogenomics, research use, and characterization work in cell and gene therapy.
By end user, the NGS reference materials market is segmented into clinical & reference laboratories, in vitro diagnostic (IVD) manufacturers, pharmaceutical & biotechnology companies, academic & research institutes, and proficiency testing & standards organizations. Clinical & reference laboratories are expected to account for the largest share in 2026, as a large number of sites perform clinical sequencing, each must validate every assay and run continuous quality control under CLIA and accreditation rules, and more hospital and regional laboratories are bringing sequencing in house. In vitro diagnostic manufacturers are expected to grow at the highest CAGR, since assay development and analytical validation for regulatory submissions consume large quantities of material, the EU IVDR requires documented characterization and traceability, and more NGS-based assays are entering regulatory review.
North America is expected to remain the largest regional NGS reference materials market in 2026, as the region performs a large volume of clinical NGS testing in oncology and inherited disease, applies strict accreditation and proficiency testing rules, hosts the NIST Genome in a Bottle program and the MDIC consensus standards work, and is home to leading suppliers such as Revvity, LGC Clinical Diagnostics, Thermo Fisher Scientific, Twist Bioscience, Maine Molecular Quality Controls, and Zymo Research. Europe holds a significant position, backed by national genomic medicine initiatives, mature clinical sequencing infrastructure, and IVDR documentation needs that make its laboratories and manufacturers early users of IVD-labeled standards.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, as clinical sequencing capacity expands quickly in China, Japan, South Korea, and India, governments invest in precision oncology and genomic medicine, domestic diagnostic companies develop their own NGS assays, and laboratories adopt international accreditation standards that bring formal validation duties. In Latin America, growing cancer sequencing in Brazil and Mexico should lift demand, while national genome programs and new clinical laboratory capacity in the Gulf countries support growth in the Middle East & Africa from a small base.
The NGS reference materials market is moderately consolidated, with a few specialist suppliers holding strong positions in clinical oncology materials, alongside broad diagnostics and life science companies, metrology institutes, and niche microbial suppliers. Suppliers compete on the breadth and clinical relevance of variant content, characterization rigor, performance at low allele frequency, commutability, lot-to-lot consistency, formats, regulatory grade, and the quality of benchmark data and support. Leading companies are adding RNA, fusion, and complex biomarker content, launching IVD-labeled grades, joining consortium standardization efforts, and building panel-matched materials. Notable developments include Revvity's June 2025 launch of IVD-labeled Mimix standards and its work with the MDIC initiative on the Mimix Geni Somatic Cancer Reference Standards, built by engineering seven cancer mutations into the Genome in a Bottle cell line GM24385.
Key companies profiled in the report include Revvity, Inc. (Horizon Discovery) (U.S.), LGC Limited (LGC Clinical Diagnostics, SeraCare) (U.K.), Thermo Fisher Scientific Inc. (U.S.), Twist Bioscience Corporation (U.S.), Maine Molecular Quality Controls, Inc. (U.S.), Zymo Research Corporation (U.S.), ATCC (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), and Microbiologics, Inc. (U.S.).
The market, also described as the NGS controls and reference standards market, includes well-characterized biological and synthetic materials of known composition that laboratories and assay makers use to build, validate, verify, and monitor next-generation sequencing tests. Cell line-derived materials in genomic DNA and FFPE formats, synthetic and engineered constructs such as plasmids, oligonucleotides, and in vitro transcribed RNA, contrived materials formulated in plasma, blood, or saliva, whole-genome and certified materials from metrology institutes, microbial and metagenomic standards are in scope, in research-use-only and IVD-labeled grades. Sequencing instruments and reagents, library preparation and extraction kits, PCR-only controls, proficiency testing services, and stand-alone software are excluded.
Sequencing capacity keeps rising, which widens the base of assays that need validation: Illumina, Inc. reported second-quarter 2026 sequencing consumables revenue of USD 775 million, up 5%, and instrument revenue of USD 125 million, up 31%. Clinical oncology testing is also growing, as Tempus AI, Inc. reported that its oncology testing volume grew 31% in the same quarter, when it also ran 9,000 residual disease tests. Standardization is also moving ahead, as NIST, through its Genome in a Bottle Consortium, supplies certified genome materials RM 8391, RM 8392, and RM 8393 together with benchmark variant call sets.
Market Dynamics
Clinical NGS growth is a major driver of the NGS reference materials market, because every assay must be validated before patient use and checked again after any change in reagent lot, instrument, or bioinformatics pipeline, and each study uses material across several replicates and allele frequency levels. The number of assays grows faster than test volume, as laboratories add panels for new tumor types, widen gene content, and begin reporting fusions, copy number changes, and other complex variant classes. Accreditation rules require continuous performance monitoring, making controls a routine purchase. Liquid biopsy and residual disease assays need plasma-like materials at very low, accurately known allele frequencies, and the shift of sequencing from large reference laboratories to hospital and regional sites multiplies the number of buyers that must run their own validation. After a U.S. District Court vacated the FDA's rule on laboratory developed tests in March 2025, laboratories carry the burden of proving analytical validity under CLIA and accreditation programs.Some large academic centers and reference laboratories rely on residual patient samples instead of commercial materials, as these specimens are commutable by nature and cost little, although they are scarce, variable, and cannot be reordered. Smaller laboratories under reimbursement pressure may cut quality control frequency, run fewer replicates, or buy narrower materials. Commutability is a major technical challenge, since engineered materials can differ from clinical samples in fragmentation, chemical modification, background complexity, and matrix, with FFPE tissue and cell-free DNA the hardest to mimic. Characterizing every variant in a multiplex material needs orthogonal methods and replicate testing, and expectations still vary between accreditation bodies and jurisdictions.
IVD-labeled and regulated-grade standards are a major opportunity; in June 2025, Revvity, Inc. launched its first IVD-labeled Mimix standards, including OncoSpan FFPE, OncoSpan gDNA, and Myeloid Cancer Panel gDNA products developed under design controls to meet FDA requirements. Under the EU In Vitro Diagnostic Regulation, makers of Class C self-declared devices were required to have a written notified body agreement in place by September 26, 2026 to continue selling legacy devices through 2028, which raises demand for documented, traceable materials. Further openings lie in RNA, fusion, and complex biomarker standards, standards that support cell and gene therapy characterization, and microbial and metagenomic controls for public health laboratories. Key trends include consortium-developed consensus materials, a shift toward multiplex and panel-matched products, and the bundling of materials with benchmark data and analytical support.
Segment Analysis
The report analyzes the market by product type, type, application, end user, and geography, helping stakeholders identify the most attractive areas for product development, partnering, and investment.By product type, the NGS reference materials market is segmented into cell line-derived, synthetic & engineered, contrived in matrix, whole-genome & certified, and microbial & metagenomic reference materials. Cell line-derived materials are expected to hold the largest share in 2026, as cell lines keep the genomic complexity of real samples so assays are tested against a realistic background, they come in genomic DNA and FFPE formats that match what clinical laboratories process, and they are long established in oncology validation, as seen in Revvity's OncoSpan and Myeloid Cancer Panel standards. Contrived materials in matrix are expected to grow at the highest CAGR, driven by liquid biopsy and residual disease testing that needs plasma-formulated materials at low, precise allele frequencies, and by growing awareness that conventional genomic DNA standards do not reflect how cell-free DNA assays perform. Synthetic and engineered materials, such as plasmid, oligonucleotide, and in vitro transcribed RNA constructs, complement cell line products.
By type, the NGS reference materials market is segmented into multiplex and single-variant reference materials. Multiplex materials are expected to account for the largest share in 2026 and to grow at the highest CAGR during the forecast period. Modern clinical panels report many genes and several variant classes, so validating them with single-variant controls would take an impractical number of samples, whereas one multiplex material can challenge many variants at once, and newer products pair DNA with RNA so that fusions are covered as well. Single-variant materials remain useful for tracking specific actionable variants and for companion diagnostic work.
By application, the NGS reference materials market is segmented into oncology, liquid biopsy & molecular residual disease, inherited & rare disease, reproductive health, infectious disease & microbiology, and other applications. Oncology is expected to account for the largest share in 2026, given the high volume of comprehensive genomic profiling, the wide range of variant classes oncology panels must cover, the clinical risk of missing an actionable variant, and the maturity of multiplex oncology materials, including consensus standards from the MDIC Somatic Reference Samples Initiative. Liquid biopsy & molecular residual disease is expected to grow at the highest CAGR, supported by fast uptake of circulating tumor DNA testing and residual disease monitoring and by the demanding specifications these assays place on reference materials. The other applications category spans pharmacogenomics, research use, and characterization work in cell and gene therapy.
By end user, the NGS reference materials market is segmented into clinical & reference laboratories, in vitro diagnostic (IVD) manufacturers, pharmaceutical & biotechnology companies, academic & research institutes, and proficiency testing & standards organizations. Clinical & reference laboratories are expected to account for the largest share in 2026, as a large number of sites perform clinical sequencing, each must validate every assay and run continuous quality control under CLIA and accreditation rules, and more hospital and regional laboratories are bringing sequencing in house. In vitro diagnostic manufacturers are expected to grow at the highest CAGR, since assay development and analytical validation for regulatory submissions consume large quantities of material, the EU IVDR requires documented characterization and traceability, and more NGS-based assays are entering regulatory review.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 17 countries and four rest-of-region groups. The regional analysis considers clinical sequencing volumes, accreditation and regulatory frameworks, standards activity, and the presence of reference material providers and diagnostic manufacturers.North America is expected to remain the largest regional NGS reference materials market in 2026, as the region performs a large volume of clinical NGS testing in oncology and inherited disease, applies strict accreditation and proficiency testing rules, hosts the NIST Genome in a Bottle program and the MDIC consensus standards work, and is home to leading suppliers such as Revvity, LGC Clinical Diagnostics, Thermo Fisher Scientific, Twist Bioscience, Maine Molecular Quality Controls, and Zymo Research. Europe holds a significant position, backed by national genomic medicine initiatives, mature clinical sequencing infrastructure, and IVDR documentation needs that make its laboratories and manufacturers early users of IVD-labeled standards.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, as clinical sequencing capacity expands quickly in China, Japan, South Korea, and India, governments invest in precision oncology and genomic medicine, domestic diagnostic companies develop their own NGS assays, and laboratories adopt international accreditation standards that bring formal validation duties. In Latin America, growing cancer sequencing in Brazil and Mexico should lift demand, while national genome programs and new clinical laboratory capacity in the Gulf countries support growth in the Middle East & Africa from a small base.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard (market leaders, market differentiators, vanguards, and emerging players), and market share/rank analysis by key player for 2025. Company profiles include business overviews, financial overviews, reference materials and product portfolios, strategic developments, and SWOT analyses.The NGS reference materials market is moderately consolidated, with a few specialist suppliers holding strong positions in clinical oncology materials, alongside broad diagnostics and life science companies, metrology institutes, and niche microbial suppliers. Suppliers compete on the breadth and clinical relevance of variant content, characterization rigor, performance at low allele frequency, commutability, lot-to-lot consistency, formats, regulatory grade, and the quality of benchmark data and support. Leading companies are adding RNA, fusion, and complex biomarker content, launching IVD-labeled grades, joining consortium standardization efforts, and building panel-matched materials. Notable developments include Revvity's June 2025 launch of IVD-labeled Mimix standards and its work with the MDIC initiative on the Mimix Geni Somatic Cancer Reference Standards, built by engineering seven cancer mutations into the Genome in a Bottle cell line GM24385.
Key companies profiled in the report include Revvity, Inc. (Horizon Discovery) (U.S.), LGC Limited (LGC Clinical Diagnostics, SeraCare) (U.K.), Thermo Fisher Scientific Inc. (U.S.), Twist Bioscience Corporation (U.S.), Maine Molecular Quality Controls, Inc. (U.S.), Zymo Research Corporation (U.S.), ATCC (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), and Microbiologics, Inc. (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global NGS reference materials market.
- Explains how clinical NGS growth, accreditation rules, liquid biopsy, and decentralized testing are shaping demand.
- Assesses the effect of commutability limits, characterization costs, residual sample use, and laboratory budgets on suppliers.
- Identifies high-growth opportunities across product type, type, application, end user, and region.
- Tracks IVD-labeled standards, consensus materials, and RNA, fusion, and complex biomarker content.
- Benchmarks leading suppliers on variant content, characterization, regulatory grade, and data support.
- Supports product planning, regulatory strategy, partnering, and market entry decisions for reference material suppliers, diagnostic manufacturers, laboratories, and investors.
Key Questions Answered
- How big is the global NGS reference materials market today, and how will it grow through 2036?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How do validation, verification, and quality control needs differ by assay type?
- How are U.S. LDT oversight and the EU IVDR changing demand for regulated-grade materials?
- What role do Genome in a Bottle, the MDIC initiative, and other consortia play in standardization?
- Which product type, type, application, and end user segments will grow the fastest?
- How are liquid biopsy and residual disease assays changing reference material specifications?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading suppliers in the market, and what strategies are they pursuing?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. NGS Reference Materials Market Assessment, by Product Type
6. NGS Reference Materials Market Assessment, by Type
7. NGS Reference Materials Market Assessment, by Application
8. NGS Reference Materials Market Assessment, by End User
9. NGS Reference Materials Market Assessment, by Geography
10. Competition Analysis
11. Company Profiles
12. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Revvity, Inc.
- LGC Limited
- Thermo Fisher Scientific Inc.
- Twist Bioscience Corporation
- Maine Molecular Quality Controls, Inc.
- Zymo Research Corporation
- ATCC
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- Microbiologics, Inc.
